Skip to content

United Therapeutics

US · UTHR #836 by market cap Listed 1970
554.73 -4.37 -0.78%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Form 144 | United Therapeutics(UTHR.US) Officer Proposes to Sell 4.69 Million in Common Stocks
    Market Newswire · 2026/11/20
  • United Therapeutics(UTHR.US) Officer Sells US$4.69 Million in Common Stock
    Market Newswire · 2026/11/20
  • Rating change
    United Therapeutics Is Maintained at Outperform by RBC Capital
    Dow Jones · 2026/11/6
  • United Therapeutics Announces First Clinical Xenotransplant In Its EXTEND Study Of UThymoKidney In Patients With ESRD
    Benzinga · 2026/11/20
  • Company notice
    United Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer ROTHBLATT MARTINE A
    SEC · 2026/11/18
  • Rating change
    Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $703
    Market Newswire · 2026/11/6
  • Rating change
    United Therapeutics Price Target Raised to $725.00/Share From $697.00 by RBC Capital
    Dow Jones · 2026/11/6
  • Rating change
    H.C. Wainwright Initiates United Therapeutics(UTHR.US) With Buy Rating, Announces Target Price $660
    Market Newswire · 2026/11/9
  • Rating change
    United Therapeutics Is Maintained at Buy by BTIG
    Dow Jones · 2026/11/5
  • Company notice
    United Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer MAHON PAUL A
    SEC · 2026/11/20
  • Company notice
    United Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
    SEC · 2026/11/20
  • Rating change
    Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $725
    Market Newswire · 2026/11/5
  • Company notice
    United Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer ROTHBLATT MARTINE A
    SEC · 2026/11/20
  • Company notice
    United Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer ROTHBLATT MARTINE A
    SEC · 2026/11/19
  • United Therapeutics(UTHR.US) Officer Sells US$5.51 Million in Common Stock
    Market Newswire · 2026/11/19
  • Rating change
    A Quick Look at Today's Ratings for United Therapeutics(UTHR.US), With a Forecast Between $650 to $768
    Market Newswire · 2026/11/5
  • United Therapeutics(UTHR.US) Officer Sells US$3.13 Million in Common Stock
    Market Newswire · 2026/11/20
  • Rating change
    United Therapeutics Is Maintained at Overweight by Wells Fargo
    Dow Jones · 2026/11/5
  • Rating change
    TD Cowen Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $700
    Market Newswire · 2026/11/5
  • Rating change
    RBC Capital Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $725
    Market Newswire · 2026/11/5
  • United Therapeutics(UTHR.US) Officer Sells US$5.5 Million in Common Stock
    Market Newswire · 2026/11/7
  • Company notice
    United Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer ROTHBLATT MARTINE A
    SEC · 2026/11/7
  • Company notice
    United Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer ROTHBLATT MARTINE A
    SEC · 2026/11/6
  • Rating change
    United Therapeutics Price Target Cut to $695.00/Share From $710.00 by JP Morgan
    Dow Jones · 2026/10/29
  • United Therapeutics Insider Sold Shares Worth $1,171,609, According to a Recent SEC Filing
    MT Newswires · 2026/11/7

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.

United Therapeutics discussion 0 comments

Add a comment